Press Releases

  • New Study Confirms VisualDx’s AI Improves Diagnostic Accuracy at the Point of Care

    A new study reveals that VisualDx's artificial intelligence solution identifies skin conditions with 68% accuracy across all skin types.

    Dec 8, 2020

  • Clinical Ink Celebrates 5 Years of Decentralized Trial Experience

    Clinical Ink, a global clinical trial technology company, today announced five years of providing clients with decentralized and hybrid trial solutions. To demonstrate our continued commitment to industry leadership and the movement toward more patient-centric clinical trials, Clinical Ink has joined the Decentralized Trials & Research Alliance (DTRA), which enables collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.

    Dec 9, 2020

  • THREAD Joins Leading Life Sciences Organizations to Advance Decentralized Clinical Research

    THREAD, an innovative technology and service provider that enables decentralized clinical research, joins a formidable alliance of 50 life sciences and healthcare organizations to accelerate the broad adoption of patient-focused decentralized clinical trials and research.

    Dec 9, 2020

  • Research reveals portable digital chest drainage systems could help minimise spread of COVID-19

    Pioneering research conducted by a team of thoracic consultants from Guy’s and St Thomas’ NHS Foundation Trust – home to one of the largest lung cancer practices in the UK – has revealed digital chest drains generate and distribute less aerosol generated particles compared to traditional water seal systems. At the start of the coronavirus pandemic there was limited evidence about the spread of COVID-19 via chest drains which led to uncertainty within the thoracic community about the best medical device to use. Researchers reviewed three different types of chest drainage systems – single chamber, 3 compartment wet-dry suction, and digital drainage system. Results showed that the 3-compartment wet-dry suction system and the digital drainage system did not generate any identifiable aerosolised particles at any of the air leak or drain output volumes considered. Medela’s Thopaz+, a digital chest drainage, and monitoring system can effectively retain pathogen-sized particles and prevent them from subsequently exiting to the environment via the exhaust. Fully supported by clinical evidence from the National Institute for Health and Care Excellence (NICE), Thopax+ is proven to improve outcomes, ensuring a safe and continuous drainage independent of a wall vacuum to provide safer patient care while minimising the risk of cross-contamination.

    Dec 9, 2020

  • CluePoints Opens New AsiaPac Office in Tokyo

    CluePoints, the premier provider of Central Statistical Monitoring, Risk-Based Quality Management and Data Quality Oversight Software for clinical trials, today announced further expansion in Japan with the opening of a new office in Tokyo. Dedicated to serving their Japanese clients, the new office builds on CluePoints’ presence in the region, as demand for modern analytical software and services enabling proactive and exhaustive identification of clinical study quality issues continues to grow. The new location, along with a team located in Osaka, will strengthen CluePoints’ growing reputation within Japan and bring it closer to its Asia-Pacific region customers.

    Dec 7, 2020

  • PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors

    PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, announced the appointment of highly experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors.

    Nov 1, 2020

  • AstraZeneca Partners with CCT to Conduct COVID-19 Vaccine Clinical Trials in Arizona

    Together with local healthcare providers, CCT will facilitate clinical trials for the AZD1222 COVID-19 VACCINE, an investigational vaccine for the prevention of COVID-19. CCT is recruiting eligible study participants who are 18 years of age or older, not pregnant, in good general health and have not been previously diagnosed with COVID-19.

    Nov 11, 2020

  • U.S. Department of Veterans Affairs Begins National Rollout of WCG’s IRBNet Research Oversight and Reporting Software as a Service (SaaS) Solution

    Software will enhance research oversight, improve transparency and expedite veterans’ access to clinical trials for more than 100 VA medical centers that have research programs

    Nov 8, 2020

  • Rho Federal Systems Division, Inc. Awarded Statistical and Data Coordinating Center Contract in BARDA Medical Countermeasures Clinical Studies Network

    Rho Federal Systems Division, Inc. Awarded Statistical and Data Coordinating Center Contract in BARDA Medical Countermeasures Clinical Studies Network CRO will serve to standardize data collection, management, and analysis across BARDA-supported network studies. Research Triangle Park, NC – November 9, 2020 – Rho, a full-service contract research organization (CRO) that helps pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, announces the Rho Federal Systems Division, Inc. (RhoFED) was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services to manage a Statistical and Data Coordinating Center (SDCC) for BARDA’s Medical Countermeasures Clinical Studies Network. Under the contract, RhoFED will be responsible for standardizing data collection, management, and analysis across BARDA-supported network studies.

    Nov 8, 2020

  • Shimmer Research Receives CE Certification for its Verisense™ Inertial Measurement Unit (IMU) Sensor for Clinical Trials

    Shimmer’s wearable sensor is now recognized as a medical device in Europe, capable of providing continuous, medical-grade measurements of a person’s activity.

    Nov 9, 2020

  • SCORR Releases 2020 Report on Health Science Company Marketing Trends

    SCORR Marketing, a global health science marketing and communications firm, has released its eighth annual survey report, Marketing Trends in Health Science Services Companies. The report is free and features data that health science executives and marketers can use to understand how companies are approaching marketing in the midst of the COVID-19 pandemic. The report provides valuable insights that can guide strategic planning, budgeting, and tactics in the year ahead.

    Nov 9, 2020

  • GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors

    GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. The study will evaluate the safety and effectiveness of GammaTile Therapy in a real-world setting in up to 50 brain tumor centers across the United States.

    Nov 9, 2020

  • eClinical Solutions Empowers the Digital Health Revolution at elluminate Engage 2020 Conference

    Annual event by eClinical goes virtual on November 18-19 to highlight digital transformation of life sciences

    Nov 11, 2020

  • Isohelix and Precision Genetics Partner to Expand COVID-19 Testing Using Saliva Collection Technology

    Isohelix announces its state-of-the-art GeneFiX™ Saliva RNA Collection Device is the technology of choice for COVID-19 testing by Precision Genetics. The high-performance, easy-to-use device marks the latest addition to Precision Genetics’ extensive portfolio of validated COVID-19 testing options submitted under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).

    Nov 11, 2020

  • Pioneering research detects Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase (HULLK) discovered in Prostate Cancer

    Pioneering research conducted by the University of Virginia in collaboration with APIS Assay Technologies has discovered Hormone-Upregulated lncRNA within lymphocyte-specific protein tyrosine kinase is detectable in non-invasive prostate cancer patient samples. The breakthrough data provides a potential new approach to address the unmet medical need of early diagnostics for prostate cancer, in combination with avoiding the invasive cancer tissue sample collection from a biopsy.

    Nov 11, 2020

  • Noxopharm Announces Pilot Study With Bristol Myers Squibb’s Product

    Australian clinical-stage drug development company Noxopharm (ASX: NOX) is pleased to announce it has joined with Bristol Myers Squibb (NYSE: BMY) in an Australian pilot study investigating the ability of Noxopharm’s immunotherapy drug candidate, Veyonda®, to overcome resistance to Bristol Myers Squibb’s nivolumab (Opdivo®) in the treatment of cancer.

    Nov 11, 2020

  • Pill Connect secures £0.5m to take electronic smart pill bottle that monitors patient adherence to commercial launch

    Pill Connect, formerly known as Elucid mHealth, has completed a £510,000 funding round to complete development of the design, electronics and software for submission to the regulatory authorities in both Europe and the US and continue through to commercial launch.

    Nov 11, 2020

  • BioIVT to Host Emerging Technologies in Diagnostics Symposium

    Advances include a rapid vaccine analysis platform, companion diagnostic for solid tumors, and bioanalytical validation methods for biomarkers and companion diagnostics

    Oct 25, 2020

  • Shimmer Solicits Clinical Research Community Input on Expanded Open Wearables Initiative (OWEAR) Vision

    As OWEAR embarks on its second year, organizers see potential to expand its positive industry impact beyond the organization’s original mission

    Oct 25, 2020

  • Protheragen Offers License Opportunities for Drug Development Programs

    Protheragen, a company founded in Ronkonkoma, New York, 2009, announces to offer license opportunities for drug R&D companies.

    Oct 26, 2020